Merck & Co., Inc. (MRK)
| Market Cap | 323.49B |
| Revenue (ttm) | 61.40B |
| Net Income (ttm) | 2.31B |
| Shares Out | 2.53B |
| EPS (ttm) | 0.90 |
| PE Ratio | 141.91 |
| Forward PE | 14.10 |
| Dividend | $3.08 (2.41%) |
| Ex-Dividend Date | Jun 17, 2024 |
| Volume | 5,644,608 |
| Open | 128.21 |
| Previous Close | 127.90 |
| Day's Range | 126.66 - 128.24 |
| 52-Week Range | 99.14 - 134.63 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 133.00 (+4.13%) |
| Earnings Date | Jul 30, 2024 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Variv... [Read more]
Financial Performance
In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $133.0, which is an increase of 4.13% from the latest price.
News
N-Power Medicine Collaborates with Merck to Expand Oncologist and Patient Access to Clinical Trials
REDWOOD CITY, Calif.--(BUSINESS WIRE)--N-Power Medicine collaborates with Merck to expand oncologist and patient access to clinical trials.
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Orion Corporation (“Orion”) today announced that notice has been provided of the mutual exer...
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30.
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH).
Global Bioreactors Market Forecast Report 2024-2035 with Key Players Profiles of Applikon Biotechnology, Bionet, Cytiva, Eppendorf, Merck, Sartorius, Solaris Biotech, Solida Biotech and LABAO
Dublin, June 28, 2024 (GLOBE NEWSWIRE) -- The "Bioreactors Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Fabrication Material, Type of Bioprocess, Type of Biologic, and Key...
CDC'S ACIP Unanimously Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--CDC'S ACIP Unanimously Recommends Merck's CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults.
Merck Stock Is Slipping. A CDC Committee Considers Pneumococcal Vaccines.
News out of a Centers for Disease Control and Prevention meeting appeared to dim the commercial prospects of Merck's new pneumococcal vaccine.
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug
The U.S. Food and Drug Administration declined to approve Merck and Japan-based Daiichi Sankyo's lung cancer treatment, which belongs to a lucrative class of cancer therapies that work like "guided mi...
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking acceler...
Healthcare: Best strategies to invest in pharma stocks
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names...
USDA Approves Merck Animal Health's NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today t...
China grants licence to Merck's KEYTRUDA for stomach cancer treatment
China's National Drug Administration has granted Merck's KEYTRUDA therapy a licence for first-line treatment of certain stomach cancer patients in the country.
Merck shares drop 10% as pharma giant scraps trial of promising cancer drug
Merck & Co's Frankfurt-listed shares fell 10% on Tuesday morning after the pharmaceutical giant said it had decided to call off a Phase III trial of its cancer drug Xevinapant, in an unexpected turn t...
Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradi...
With Robust AI Prospects Is IBM A Better Pick Over Merck Stock Within The Dow Index?
We believe that the computing behemoth IBM (NYSE: IBM) is currently a better pick over the pharmaceuticals giant Merck (NYSE: MRK). The decision to invest often comes down to finding the best stocks w...
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these...
Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval
Pfizer currently dominates the market for pneumococcal vaccines. Merck aims to change that.
FDA approves Merck's pneumonia vaccine for adults
The Food and Drug Administration (FDA) has approved Merck's (MRK) new vaccine to protect adults from pneumonia. Yahoo Finance's Anjalee Khemlani reports more on how the vaccine works as the pharmaceut...
US FDA approves Merck's pneumococcal vaccine for adults
Merck said on Monday the U.S. Food and Drug Administration has approved its next-generation vaccine to protect adults against pneumococcal disease.
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease & Pneumococcal Pneumonia in Adults.
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves Merck's KEYTRUDA Plus Chemotherapy as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma.
FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections
The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia. An ad...
Merck's vaccine approval poses threat to one of Pfizer's top-selling products
Merck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.'s top-selling products.
Merck looks for next-generation opportunities in obesity
Merck is focused on second and third-generation opportunities in the cardiometabolic drugs market, which includes treatments for obesity, the drugmaker said at a healthcare conference on Tuesday.